Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2019

Open Access 01-06-2019 | Breast Cancer | Epidemiology

Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors

Authors: Gitana Maria Aceto, Khalid Dafaallah Awadelkarim, Marta Di Nicola, Carmelo Moscatello, Mattia Russel Pantalone, Fabio Verginelli, Nasr Eldin Elwali, Renato Mariani-Costantini

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Login to get access

Abstract

Purpose

The role of non-genetic factors as modifiers of TP53-related hereditary breast cancer (BC) risk is debated. In this regard, little is known about the impact of germline TP53 mutations on BC in sub-Saharan Africa, where the disease often presents in non-contraceptive multiparous premenopausal women with extended history of breastfeeding. Herein, we report the germline TP53 mutations found in a series of 92 Sudanese premenopausal BC patients characterized for reproductive history.

Methods

The entire TP53 coding sequence, including intron–exon boundaries and UTRs, was analyzed via DHPLC and direct sequencing, and the association of TP53 genotypes with BC risk and with individual lifetime exposures to reproductive factors was investigated with statistical tools.

Results

The germline TP53 mutation spectrum comprised 20 variants, 15 in the non-coding and 5 in the coding region. The latter included a deleterious missense mutation, c.817C>T (p.Arg273Cys), in a unique patient, and the common and functionally relevant coding polymorphism at amino acid 72 [Pro72Arg (rs1042522)]. The non-coding mutations included c.919+1G>A, a known deleterious splice site mutation, also in a unique patient. Notably, the 2 carriers of deleterious TP53 mutations clustered in the subset of cases with stronger reproductive history relative to childbearing age. When analyzed in comparison to population controls, the codon 72 polymorphism did not reveal associations with BC.

Conclusions

Our study suggests that the codon 72 Arg>Pro polymorphism is not implicated in premenopausal BC susceptibility, whereas multiparity and breastfeeding might be BC risk factors for carriers of deleterious TP53 mutations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS, Savage SA (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122(23):3673–3681CrossRefPubMed Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS, Savage SA (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122(23):3673–3681CrossRefPubMed
2.
go back to reference Amadou A, Waddington Achatz MI, Hainaut P (2018) Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol 30(1):23–29CrossRefPubMed Amadou A, Waddington Achatz MI, Hainaut P (2018) Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol 30(1):23–29CrossRefPubMed
3.
go back to reference Lalloo F, Varley J, Moran A, Ellis D, O’dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42(8):1143–1150CrossRefPubMed Lalloo F, Varley J, Moran A, Ellis D, O’dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42(8):1143–1150CrossRefPubMed
4.
go back to reference Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian breast cancer family study. Cancer Res 70(12):4795–4800CrossRefPubMedPubMedCentral Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian breast cancer family study. Cancer Res 70(12):4795–4800CrossRefPubMedPubMedCentral
5.
6.
go back to reference Awadelkarim KD, Arizzi C, Elamin EO, Hamad HM, De Blasio P, Mekki SO, Osman I, Biunno I, Elwali NE, Mariani-Costantini R et al (2008) Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology 52(4):445–456CrossRefPubMed Awadelkarim KD, Arizzi C, Elamin EO, Hamad HM, De Blasio P, Mekki SO, Osman I, Biunno I, Elwali NE, Mariani-Costantini R et al (2008) Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology 52(4):445–456CrossRefPubMed
7.
go back to reference Mariani-Costantini R (2013) Diagnosis: breast cancer screening in rural African communities. Nat Rev Clin Oncol 10(4):185–186CrossRefPubMed Mariani-Costantini R (2013) Diagnosis: breast cancer screening in rural African communities. Nat Rev Clin Oncol 10(4):185–186CrossRefPubMed
8.
go back to reference Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I (2016) Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health 4(12):e923–e935CrossRefPubMedPubMedCentral Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I (2016) Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health 4(12):e923–e935CrossRefPubMedPubMedCentral
9.
go back to reference Abbad A, Baba H, Dehbi H, Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O, Radouani F (2018) Genetics of breast cancer in African populations: a literature review. Glob Health Epidemiol Genom 3:e8CrossRefPubMedPubMedCentral Abbad A, Baba H, Dehbi H, Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O, Radouani F (2018) Genetics of breast cancer in African populations: a literature review. Glob Health Epidemiol Genom 3:e8CrossRefPubMedPubMedCentral
10.
go back to reference Macaulay S, Goodyear QC, Kruger M, Chen W, Essop F, Krause A (2018) The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome. Fam Cancer 17(4):607–613CrossRefPubMed Macaulay S, Goodyear QC, Kruger M, Chen W, Essop F, Krause A (2018) The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome. Fam Cancer 17(4):607–613CrossRefPubMed
11.
go back to reference Awadelkarim KD, Aceto G, Veschi S, Elhaj A, Morgano A, Mohamedani AA, Eltayeb EA, Abuidris D, Di Gioacchino M, Battista P et al (2007) BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. Breast Cancer Res Treat 102(2):189–199CrossRefPubMed Awadelkarim KD, Aceto G, Veschi S, Elhaj A, Morgano A, Mohamedani AA, Eltayeb EA, Abuidris D, Di Gioacchino M, Battista P et al (2007) BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. Breast Cancer Res Treat 102(2):189–199CrossRefPubMed
12.
go back to reference Biunno I, Aceto G, Awadelkarim KD, Morgano A, Elhaj A, Eltayeb EA, Abuidris DO, Elwali NE, Spinelli C, De Blasio P et al (2014) BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan. Fam Cancer 13(3):437–444CrossRefPubMed Biunno I, Aceto G, Awadelkarim KD, Morgano A, Elhaj A, Eltayeb EA, Abuidris DO, Elwali NE, Spinelli C, De Blasio P et al (2014) BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan. Fam Cancer 13(3):437–444CrossRefPubMed
13.
go back to reference United Nations, Department of Economic and Social Affairs, Population Division (2017). World Fertility Data 2017 (POP/DB/Fert/Rev2017) United Nations, Department of Economic and Social Affairs, Population Division (2017). World Fertility Data 2017 (POP/DB/Fert/Rev2017)
14.
go back to reference Verselis SJ, Rheinwald JG, Fraumeni JF, Li FP (2000) Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene 19(37):4230–4235CrossRefPubMed Verselis SJ, Rheinwald JG, Fraumeni JF, Li FP (2000) Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene 19(37):4230–4235CrossRefPubMed
15.
go back to reference Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622–629CrossRefPubMed Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622–629CrossRefPubMed
16.
go back to reference Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, Bonnen PE, de Bakker PI, Deloukas P, Gabriel SB et al (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467(7311):52–58CrossRefPubMed Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, Bonnen PE, de Bakker PI, Deloukas P, Gabriel SB et al (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467(7311):52–58CrossRefPubMed
17.
go back to reference Sudan Nutrition Profile (2005) Food and Nutrition Division, Food and Agriculture Organization of the United Nations Sudan Nutrition Profile (2005) Food and Nutrition Division, Food and Agriculture Organization of the United Nations
18.
go back to reference Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C (2004) Detection of large-scale variation in the human genome. Nat Genet 36(9):949–951CrossRefPubMed Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C (2004) Detection of large-scale variation in the human genome. Nat Genet 36(9):949–951CrossRefPubMed
19.
go back to reference van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW, Slagboom PE, Westendorp RG (2005) group LLs: variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40(1–2):11–15CrossRefPubMed van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW, Slagboom PE, Westendorp RG (2005) group LLs: variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40(1–2):11–15CrossRefPubMed
20.
go back to reference Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9(2):95–107CrossRefPubMed Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9(2):95–107CrossRefPubMed
21.
go back to reference Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357–365CrossRefPubMed Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357–365CrossRefPubMed
22.
go back to reference Jeong BS, Hu W, Belyi V, Rabadan R, Levine AJ (2010) Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J 24(5):1347–1353CrossRefPubMed Jeong BS, Hu W, Belyi V, Rabadan R, Levine AJ (2010) Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J 24(5):1347–1353CrossRefPubMed
23.
go back to reference Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9(3):R34CrossRefPubMedPubMedCentral Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9(3):R34CrossRefPubMedPubMedCentral
24.
go back to reference Basu S, Gnanapradeepan K, Barnoud T, Kung CP, Tavecchio M, Scott J, Watters A, Chen Q, Kossenkov AV, Murphy ME (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α. Genes Dev 32(3–4):230–243CrossRefPubMedPubMedCentral Basu S, Gnanapradeepan K, Barnoud T, Kung CP, Tavecchio M, Scott J, Watters A, Chen Q, Kossenkov AV, Murphy ME (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α. Genes Dev 32(3–4):230–243CrossRefPubMedPubMedCentral
25.
go back to reference Lawson JS, Glenn WK, Salyakina D, Delprado W, Clay R, Antonsson A, Heng B, Miyauchi S, Tran DD, Ngan CC et al (2015) Human Papilloma viruses and breast cancer. Front Oncol 5:277CrossRefPubMedPubMedCentral Lawson JS, Glenn WK, Salyakina D, Delprado W, Clay R, Antonsson A, Heng B, Miyauchi S, Tran DD, Ngan CC et al (2015) Human Papilloma viruses and breast cancer. Front Oncol 5:277CrossRefPubMedPubMedCentral
26.
go back to reference Eltahir HA, Adam AA, Yahia ZA, Ali NF, Mursi DM, Higazi AM, Eid NA, Elhassan AM, Mohammed HS, Ibrahim ME (2012) p53 codon 72 arginine/proline polymorphism and cancer in Sudan. Mol Biol Rep 39(12):10833–10836CrossRefPubMed Eltahir HA, Adam AA, Yahia ZA, Ali NF, Mursi DM, Higazi AM, Eid NA, Elhassan AM, Mohammed HS, Ibrahim ME (2012) p53 codon 72 arginine/proline polymorphism and cancer in Sudan. Mol Biol Rep 39(12):10833–10836CrossRefPubMed
27.
go back to reference Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J (2013) A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis 4:e492CrossRefPubMedPubMedCentral Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J (2013) A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis 4:e492CrossRefPubMedPubMedCentral
28.
go back to reference Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control 13(4):299–305CrossRefPubMed Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control 13(4):299–305CrossRefPubMed
29.
go back to reference Díaz-Cruz ES, Furth PA (2010) Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia. Cancer Res 70(10):3965–3974CrossRefPubMedPubMedCentral Díaz-Cruz ES, Furth PA (2010) Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia. Cancer Res 70(10):3965–3974CrossRefPubMedPubMedCentral
Metadata
Title
Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors
Authors
Gitana Maria Aceto
Khalid Dafaallah Awadelkarim
Marta Di Nicola
Carmelo Moscatello
Mattia Russel Pantalone
Fabio Verginelli
Nasr Eldin Elwali
Renato Mariani-Costantini
Publication date
01-06-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05168-1

Other articles of this Issue 2/2019

Breast Cancer Research and Treatment 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine